Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

Omeros (OMER) received a negative opinion from the CHMP for its narsoplimab marketing application in Europe. The drug, approved in the U.S. as YARTEMLEA, is the only therapy for TA-TMA. Omeros plans to terminate the compassionate-use program due to U.S. demand and is pursuing additional indications.

Original reporting
Published Oct 16, 2026, 10:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 11:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$OMER
Bearish
high confidence
Mentioned
$OMER
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$OMERBearishMed
01

Why it matters

The negative CHMP opinion removes a key growth avenue, likely prompting a share price decline.

02

Market read

Regulatory decision directly affects OMER's valuation and may influence related biotech stocks.

03

What to watch

Potential for a future appeal or alternative EU partnership could mitigate impact.

Relevance 8/10Novelty 8/10Timing: today

Background

Omeros' YARTEMLEA is the only FDA‑approved therapy for TA‑TMA and has no EU approval.

Company-level read

Ticker impact

$OMERBearishHigh confidence
Context

CHMP issued a negative opinion on OMER's EU marketing authorization for narsoplimab, a fresh regulatory setback.

Expected impact

downward pressure as market prices in the regulatory denial

Evidence & confidence

Regulatory outcomes drive biotech valuations; a negative EU opinion reduces future revenue potential and may trigger sell‑offs.

Market effects

Other complement‑inhibitor biotech firms may see heightened scrutiny.

European biotech stocks could face short‑term weakness.

Limited to OMER and peers in the complement‑therapy space.

Counterpoint

If OMER can secure US market growth, the EU setback may be priced out quickly.

Key entities

  • Omeros Corporation

    Biotech developer of YARTEMLEA (narsoplimab).

  • CHMP

    Committee for Medicinal Products for Human Use, part of EMA.

Related articles

$OMERMed

OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares

Omeros (OMER) shares are down, heading for their worst day in 18 months. The company delayed Q4 and 2027 sales guidance, citing uncertainty. A clinical trial for OMS527 was postponed to 2027 due to delays in acquiring study animals. Despite this, retail sentiment on Stocktwits turned bullish, focusing on Yartemlea's launch and a partnership with Novo Nordisk. OMER stock is down 22% year-to-date.

$OMERMed

Omeros (OMER) Q3 2026 Earnings Call Transcript

Omeros (OMER) reported Q3 2026 earnings with YARTEMLEA generating $35.9M in net sales, up 26% from Q2. GAAP net loss was $57.4M, but non-GAAP net income was $4.7M. The company reduced convertible notes and repurchased shares. YARTEMLEA saw increased adoption and reimbursement advantages.

$OMERMed

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 10.4% in after-hours trading after reporting Q3 2026 results. The company reported a GAAP net loss of $57.4 million, or $0.79 per share, due to a $62.0 million non-cash loss. Adjusted EPS of $0.06 beat estimates, and revenue exceeded expectations. A negative opinion from the European Medicines Agency on narsoplimab also weighed on sentiment.

$OMERMedAI 8/10

Omeros falls 10% despite revenue beat

Omeros (NASDAQ:OMER) reported Q3 revenue of $41.8M, beating estimates, but shares fell 10% due to a widened GAAP net loss of $57.4M. Adjusted earnings were $0.06 per share, exceeding expectations. YARTEMLEA sales grew 30% sequentially. The company held $95.3M in cash as of Q3 2026.

$OMERMed

Omeros Corporation Reports Third Quarter 2026 Financial Results

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Third Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – November 16, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third q